Icagen brings more than two decades of experience in ion channel drug discovery research and development including voltage-gated sodium (Nav) channels, which are important drug development targets for a wide variety of therapeutic indications including pain, epilepsy and cardiac rhythm disorders.

Icagen has recently expanded its capabilities to offer state of the art 384-well high fidelity automated electrophysiology assays employing the Nanion Syncropatch 384PE platform. Icagen provides cost effective, high capacity rapid turnaround assays, enabling evaluation of drug candidate activity across a variety of therapeutically important Nav channels including neuronal Nav1.1 and Nav1.7 channels as well as the cardiac Nav1.5 channel. Icagen assays can simultaneously determine compound potency under different gating states as well as selectivity across Nav channel subtypes.

For more information, contact info@icagen.com or visit our website www.icagen.com